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Abstract
Background
Fertility rates in Europe are among the lowest in the world, which may be attributed to both
biological and lifestyle factors. Cost and reimbursement of fertility treatments vary across
Europe, although its citizens enjoy wide access to fertility care. Since few regional studies
evaluating public support for fertility treatment exist, we conducted the Listening IVF and
Fertility in Europe (LIFE) survey to ascertain public perception of in vitro fertilization (IVF)
and gamete donation as a treatment for infertility among European men and women.
Methods and findings
This survey was distributed via an online questionnaire to 8,682 individuals who were volun-
tary participants in an online research panel residing in France, Germany, Italy, Spain, Swe-
den, or the UK. The survey covered items to determine respondents’ beliefs regarding IVF
and its success, the need for public funding, the use of IVF among modern families with dif-
ferent lifestyles, and the support for gamete donation. Results were analyzed by age, coun-
try of origin, sex, and sexual orientation. A total of 6,110 (70% of total) men and women
responded. Among all respondents, 10% had undergone IVF treatment and 48% had con-
sidered or would consider IVF in case of infertility. Respondents estimated IVF mean suc-
cess rate to be 47% and over half of respondents believed that availability of IVF would
encourage people to delay conception. Although 93% of respondents believed that IVF
treatment should be publicly funded to some extent, a majority believed that secondary
infertility or use of fertility treatments allowing to delay parenthood should be financed pri-
vately. Survey respondents believed that the mean number of stimulated IVF cycles funded
publicly should be limited 2 to 3 (average 2.4). 79% of respondents were willing to pay for
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IVF if needed with a mean amount of 5,400 € for a child brought to life through IVF. Accord-
ing to respondents, mean minimum and maximum ages for IVF should be 29 and 42 years
old, respectively. The current survey showed support for egg and sperm donation (78%), for
IVF in single women (61%) and for same-sex female couples (64%). When analyzing the
results per group (i.e., sex, age, sexual orientation, and countries), youngest age groups,
homosexuals, bisexuals, German respondents, and men had similar overall positive atti-
tudes and beliefs toward IVF and opinions on public funding. Perceived limits to availability
were stronger in women.
Conclusion
Overall, the survey results demonstrate a positive attitude among respondents in an online
panel toward IVF, gamete donation, and support for public funding for fertility treatment.
These findings could potentially drive discussions between patients and prescribers to
explore IVF treatment and among legislators and payers to support public funding for these
procedures.
Introduction
Since the development of assisted reproductive technologies (ART), also referred to as medi-
cally assisted reproduction [1], couples with reduced fertility or advanced age, single women,
and same-sex couples now have options to experience parenthood. The evolution of and
increased access to fertility treatments have resulted in a substantial increase in number of
babies born via in vitro fertilization (IVF) since the first IVF baby was born in 1978. According
to the most recent available data published by the International Working Group for Registers
on Assisted Reproduction and the International Committee for Monitoring Assisted Repro-
ductive Technology, infants born annually via ART in countries reporting, increased approxi-
mately 40-fold from 11,323 [2] in 1989 to 404,364 in 2010 [3].
A wealth of information about ART exists on the internet [4], but current public percep-
tions of ART are still unknown because attitude surveys are outdated (almost >20 years ago),
limited in size [5], or limited to those participating in gamete transfers [6–8], to other specific
populations (such as infertile patients, students, childless individuals, or healthcare profession-
als), or to participants from individual countries [9–17].
The current survey, conducted online, involving a panel comprised of participants residing
in France, Germany, Italy, Spain, Sweden, or the UK, queried over 6,000 men and women
regarding IVF and gamete donation to ascertain their opinion concerning ART, its funding,
and perceived limits towards its availability.
Materials and methods
Survey method
The web-based survey was conducted by CENSUSWIDE: The Survey Consultants (London, UK),
whose methodology [18] complies with the Market Research Society (MRS) Code of Conduct
rules (2010) [19]. The MRS rules are based on the International Chamber of Commerce/
World Association of Opinion and Marketing Research Professionals (ICC/ESOMAR) Inter-
national Code on Market, Opinion and Social Research Data Analytics [20]. Surveys were sent
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any point in accordance with the MRS rules [19]. Accordingly, no responses from “part com-
pleted” interviews were included in the results since it could not be guaranteed that the respon-
dent had not revoked their consent to participate. Respondents had the opportunity to go back
to previous items and change their answers.
The panels were recruited with the aim of having a balanced sample across all demograph-
ics, and the invitation was sent out randomly to achieve a broad sample. In the panel, the num-
ber of participants were proportional to the number of inhabitants of each country region. In
the study population, the number of respondents of a given country region was proportional
to that region. Thus, there was an attempt to create a representative panel. The panel of each
country surveyed was characterized by region of residence, gender, and age, and—for the UK
only—with regard to socioeconomic status (SES).
CENSUSWIDE continued to recruit respondents until reaching the target of at least 1000
respondents per country; thus, the absolute number of surveys sent per country was based on
the country’s response rate.
This survey met the requirements for institutional review board exemption as listed in 45
CFR 46.101(b). Participant information was recorded in such a manner that the human sub-
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Population
The survey population was a sample of people who previously agreed to participate in a social
research panel. Invitations to the survey were sent to participants residing in 6 large Western
European countries with different reimbursement policies of IVF treatment and different
healthcare systems. Demographic information was not a selection criterion, but limited char-
acteristics were recorded. Because the sample was made up of volunteers, females were slightly
more represented in the panels than males in most countries, apart from Italy and Germany.
In addition, the population aged 16–44 was over-represented in all panels (roughly 70%) com-
pared to the country population (between 45% and 50%). In the UK, the only country where
SES was known, the panel was representative of SES of the general population.
Questionnaire (see S1 Appendix)
The current analysis focuses on IVF reporting on responses to 12 distinct items within the
questionnaire that explored respondent opinions on IVF treatment and gamete donation. Spe-
cifically, topic areas were acceptance of IVF (including experience using IVF and willingness
to use IVF) (Item 1); perceived success rate of IVF (Item 2); age limits regarding use of IVF
(Item 3); payment for IVF (public/government funding) (Item 4); number of IVF cycles to be
funded (Item 5); criteria that should be used to support government/public funding for IVF
(Item 6); payment for IVF (individual couple) (Item 7); opinions related to the use of IVF by
individuals who were single (Item 8) or same sex female couples (Item 9); opinions of IVF use
likely increasing over the next few years (Item 10); opinions on the potential for delay of con-
ception due to availability of IVF (Item 11); and support for gamete donation (egg and sperm)
(Item 12). The remaining 10 questionnaire items relate primarily to fertility preservation and
will be reported separately.
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Statistical analysis
Questionnaire responses were analyzed according to sex, age, sexual orientation, and country
using SAS version 9.4 (SAS Institute Inc., Cary, NC). Frequencies across responses to individ-
ual items and demographic groups using Pearson’s Chi square tests were performed to investi-
gate differences in frequencies between demographic categories (i.e., age group, sex, sexuality,
country) and by survey item.
In addition to individual items (See S1 Appendix for questionnaire items and response
scales), composite scores were computed for 3 categories. For the 3 categories, attitudes to IVF
were measured using items that were combined to form a total favorability score. Items were
summed and dichotomized into 0 (no favorable item) to 1 (favorable on at least one item) then
assigned to equal binary categories of “low” and “high”. Average numerical values were calcu-
lated based on the mean of the midpoint of each value or age band selected by each respondent.
The following 3 categories were analyzed:
1. Beliefs and attitude toward IVF treatment: Item 1 (“Would you/have you ever considered
using IVF treatment?”), Item 2 (“What do you think the success rate of becoming pregnant
through IVF is?”), and Item 11 (“Do you think that the availability of IVF treatment encour-
ages people to delay conception?”)
2. Funding: Item 4 (circumstances under which IVF treatment should privately or publicly
funded), Item 5 (maximum number of rounds of IVF that the government should fund for
any individual/couple), and Item 7 (“How much would you pay to have a child through
IVF?”)
3. Perceived limit to availability: Item 3 (“What do you think should be the minimum and
maximum age limit for acceptance for IVF treatment?”), Item 8 (“Do you believe that IVF
treatment should be available to single women without a partner?” [in this situation, sperm
would be provided by a donor]), Item 9 (“Do you believe that IVF treatment should be
available to same sex female couples?” [in this situation, sperm would be provided by a
donor]), and Item 12 (“Do you support the practice of egg donation and sperm donation?”)
Chi square tests were performed to test for differences across each demographic category
for each binary concept. Differences were considered significant if the probability of the calcu-
lated difference in frequency was less than a value of 0.05, representing a rejection of the null
hypothesis of no difference in frequencies between groups.
Results
Response rate and demographic characteristics of the sample
A total of 8,682 individuals were contacted via e-mail and asked to participate and 6,610 indi-
viduals responded to all questionnaire items (70% response rate). Response rates were highest
in the UK and Italy (89% and 90%, respectively) as compared with Sweden and France (55%
and 56%, respectively).
Among respondents, there were marginally more males than females (Table 1), and the
large majority (88%) was heterosexual. The age groups most represented were 25–34 years and
35–44 years.
Beliefs and attitude toward IVF treatment
Regarding acceptance of IVF (Item 1), more than half of the respondents (54%) had consid-
ered or would consider having IVF treatments (Fig 1). Nearly 10% of the respondents had
Public perception of IVF in Europe
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undergone IVF treatment. Among the various groups analyzed, a greater proportion of male
respondents compared to female respondents (P<0.001) and homosexuals (63%) and bisexu-
als (82%) compared to heterosexual respondents (57%) (P<0.003) had IVF or had considered/
would consider IVF. Fewer respondents from France and Germany compared with respon-
dents from other countries (P<0.001) and a higher proportion of respondents belonging to
the youngest age groups (16–24 and 25–34 years) as compared to the older age groups
(P<0.001) had IVF or had considered/would consider IVF.
When asked to estimate the success rate of becoming pregnant through IVF (Item 2), the
overall mean response was 47%. Sixty percent of all respondents estimated IVF success rates as
higher than 40%. Only 16% believed that IVF was successful�20% of the time. UK respon-
dents gave the lowest mean IVF success rates (40%). Success rates tended to be estimated as
higher than 40% more often by men (61%; P<0.001), respondents age 25–34 years (63%;
P<0.001), homosexual respondents (61%, P<0.001), and respondents from Spain (79%,
P<0.001).
In response to Item 11 (“Do you think that the availability of IVF treatment encourages
people to delay conception?”), over half of the respondents answered “yes” (52%), with 54% of
men (P<0.001), 55% of respondents in age groups 25–34 (P<0.001), 53% of respondents 55+
years (P<0.001), and 59% of respondents from France and Germany (P<0.001) responding
“yes”. In response to Item 10 (“Do you think the use of IVF treatment will increase over the
next 5 years?”), more than 3 respondents out of 4 believe that use of IVF treatment will
increase in the next 5 years.
When items were grouped into the category “Attitude and beliefs,” scores from men
(P<0.001), respondents age 25–34 (P<0.001), homosexual respondents (P<0.001), and
respondents from France and Germany were ranked higher compared with scores from other
groups. The lowest ranked attitudes and beliefs were recorded from respondents from Sweden
(P<0.001).
Table 1. Characteristics of study population.
UK
N (%)
France
N (%)
Germany
N (%)
Italy
N (%)
Spain
N (%)
Sweden
N (%)
Total
N (%)
Total� 1,043 (17) 1,022 (17) 1,011
(17)
1,024 (17) 1,003 (16) 1,005 (16) 6,110 (100)
Sex
Male 408 (39) 440 (43) 562 (56) 454 (44) 611 (61) 674 (67) 3,149 (52)
Female 635 (61) 552 (54) 449 (44) 570 (56) 392 (39) 331 (33) 2,961 (48)
Age
16–24 131 (13) 86 (8) 123 (12) 69 (7) 87 (9) 236 (23) 733 (12)
25–34 298 (29) 198 (19) 247 (24) 246 (24) 285 (28) 329 (33) 1,603 (26)
35–44 205 (20) 293 (29) 224 (22) 318 (31) 338 (34) 221 (22) 1,599 (26)
45–54 205 (20) 242 (24) 209 (21) 245 (24) 199 (20) 125 (12) 1,225 (20)
55+ 204 (20) 203 (20) 208 (21) 146 (14) 94 (9) 94 (9) 950 (16)
Sexual orientation
Heterosexual 936 (90) 928 (91) 853 (84) 958 (94) 930 (93) 791 (79) 5,398 (88)
Bisexual 40 (4) 42 (4) 42 (4) 23 (2) 30 (3) 80 (8) 257 (4)
Homosexual 31 (3) 24 (2) 43 (4) 13 (1) 26 (3) 36 (4) 173 (3)
Information not provided 36 (3) 28 (3) 73 (7) 30 (3) 17 (2) 98 (10) 282 (5)
�The distribution of respondents by country is similar despite differences in response rate by country because surveys continued to be sent until the target number of
responses (~1,000) had been received from each country.
https://doi.org/10.1371/journal.pone.0211150.t001
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Fig 1. Degree of acceptance of IVF (A) among all respondents; (B) by sex; (C) by country; (D) by age. Respondents could select
more than 1 response. Please refer to the questionnaire for full response text.
https://doi.org/10.1371/journal.pone.0211150.g001
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Attitudes toward funding
Regarding the number of IVF attempts to be publicly funded (Item 5), 93% of respondents
answered that at least one IVF cycle should be publicly funded (Fig 2). Overall, the responses
indicated that a mean of 2.4 cycles should be publicly funded. By group, the number was
higher when answered by women, respondents age 25–34, homosexual and bisexual respon-
dents, and respondents from Sweden and France; all P<0.001.
When asked why they believed there should be a maximum limit to the number of publicly
funded IVF cycles (Item 6), about half (52%) answered “because there are other ways to have a
child” and “Because there are better ways of allocating healthcare funds raised by taxpayer
money (i.e., into other medical issues)” (48%).
When asked about circumstances that might influence whether IVF treatment should be
privately or publicly funded (Item 4), respondents agreed that funding of treatment should
vary with certain circumstances (Fig 3). The majority of respondents agreed that circum-
stances such as primary infertility and decreased fertility secondary to treatment for medical
conditions (i.e., cancer) should be publicly funded. By contrast, after having a first child or
when a couple decides to have a child later in life, the majority of respondents indicated that
IVF should be financed privately. Of interest, 23% of respondents believed that IVF treatment
should not be available to delay parenthood.
Information about willingness to pay to have a child utilizing IVF (and ranges for amounts
they are willing to pay [in €]) (Item 7) is shown in Fig 4. Overall, 57% were willing to pay at
least 1,000 €, with a mean amount of 5,400 € for a child brought to life through IVF. More
than 20% of all respondents indicated they were unwilling to pay any sum of money for IVF
treatment. An even higher proportion of respondents in the age 45–54 (27%) and 55+ (40%)
groups and respondents from France (29%) were unwilling to pay for IVF. Respondents will-
ing to pay the highest amount were in the age 16–24 group (mean of 6,800 €), compared to
other age groups; the mean amount that respondents from Spain, Sweden, and the UK would
pay was similar (6,100 €-6,900 €) and higher than France and Germany (3,600 €-5,000 €).
However, when willingness to pay a “high value” was analyzed, no differences were observed
in responses according to sex (P = 0.056) or sexual orientation (P = 0.16).
Fig 2. Opinions regarding the number of publicly funded IVF cycles.
https://doi.org/10.1371/journal.pone.0211150.g002
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The analysis of the funding category showed that overall attitude and beliefs toward funding
were ranked higher in men, the 2 lowest age groups (16–24 and 25–34), heterosexual respon-
dents, and respondents from Germany, Spain, and the UK (lowest in respondents from Swe-
den) compared with other groups (P<0.001 for all comparisons).
Perceived limits to availability of IVF treatment and gamete donation
Respondents’ opinions about the minimum and maximum age for IVF treatment (Item 3) are
presented in Fig 5. The mean minimum age for IVF overall was 29 years, while the mean maxi-
mum age was 42.
Fig 3. Opinions regarding the funding source for IVF. See questionnaire for full response text.
https://doi.org/10.1371/journal.pone.0211150.g003
Fig 4. Acceptable cost for IVF (in €). Mean acceptable cost: 5,400 €.
https://doi.org/10.1371/journal.pone.0211150.g004
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The mean minimum age for IVF was similar between men and women (29 years), was
lower in the youngest age group (28 years) as compared to the other age groups (29–30 years)
and respondents from Spain (28 years) and was higher in respondents from Sweden (31
years). As for mean maximum age, it was slightly higher in women than in men (43 versus 42
years), in age groups 35–44 and 45–55 (43 years) as compared to other age groups, and in
respondents from Spain and Italy (44 years).
Regarding items about whether IVF access should be granted to single women (Item 8) and
to same-sex female couples (Item 9), the overall majority agreed that it should (61% and 64%,
respectively). More women than men agreed (64% vs 58% about single women and 67% vs
62% about same-sex female couples; P<0.001). Respondents from the youngest age group
agreed more frequently than those in the oldest age group (70% and 79% in 16–24 age group
versus 45% and 47% in 55+ age group, P<0.001). Most bisexuals and homosexuals agreed that
single women and same sex female couples should have access to IVF, respectively (74%, 71%,
and 85%, 81% compared to heterosexuals who agreed 60% and 63% of the time; P<0.001).
Respondents from Spain had the highest level of agreement with availability of IVF to single
women and same-sex female couples (81% and 82%), whereas respondents from Italy had the
least (50% and 46%); all P<0.001.
A large majority of respondents supported both egg donation and sperm donation (78% for
both) (Item 12), by selecting “yes” as their response, with 79% of women and 76% of men sup-
porting egg donation (P = 0.02) and sperm donation (P = 0.002). More respondents from the
two youngest age groups supported egg donation and sperm donation (80% to 81% versus
72% to 77% in the older age groups; P<0.001 for both). More bisexuals and homosexuals than
heterosexuals supported egg and sperm donations (80% to 88%, P<0.002 versus 78% for
both). Among the various countries, respondents from Spain supported gamete donation
most often and those from Italy least often (92% to 93% versus 61% to 63%; P<0.001 for both).
Perceived limits to IVF availability as derived by combining items on age limit, availability
of IVF to single women and same sex female couples, and support of gamete donation were
ranked higher in women than in men, higher in the two youngest age groups (16–24 and 25–
35) as compared to other age groups, higher in homosexuals and bisexuals compared to
Fig 5. Minimum and maximum acceptable age ranges for IVF.
https://doi.org/10.1371/journal.pone.0211150.g005
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heterosexuals and higher in respondents from Germany compared to other countries, with the
lowest rank recorded from respondents from France (P<0.001 for all comparisons).
Discussion
To our knowledge, the current LIFE survey represents the largest study performed so far con-
cerning public opinion regarding ART with over > 6,000 respondents across Europe. The
respondents expressed favorable attitudes in relation to IVF and its success, the need for public
funding, the use of IVF among modern families with different lifestyles, and support for gam-
ete donation. The youngest age groups, homosexuals, bisexuals, German respondents, and
men had similar overall positive attitudes and beliefs toward IVF and opinions in relation to
public funding and perceived limits to availability. Perceived limits to availability were stron-
ger in women. These differences in acceptability, beliefs, and perception should be taken into
consideration for future research or when designing awareness campaigns or other initiatives
in these groups. The survey revealed over-optimism about success of IVF which may lead to
too much reliance on IVF as a mean to overcome infertility.
Previously, fertility knowledge and treatment attitudes were investigated in 10,045 individ-
uals actively trying to conceive (International Fertility Decision-Making Survey, IFDMS) [21].
Both positive (safety, efficacy) and negative views (physical/emotional effects) on fertility treat-
ments were reported. Negative beliefs were strongly associated with higher fertility knowledge
and were mostly observed in women, people with a university education, with employment,
living in the more economically developed countries, childless individuals and those trying to
conceive for more than a year. Although the items used to assess attitude toward IVF treatment
were different in our survey, current results clearly indicate a more favorable attitude. One
explanation may be the different surveyed populations for LIFE and the IFDMS. The IFDMS
largely represented people with [failed] fertility treatment experience (about 70%), whereas the
LIFE survey comprised an untreated sample from the general population with little treatment
experience (<10%). It is also possible that social normative view has changed over time as IVF
has become more main stream technology.
Variations in attitudes towards IVF were observed in our survey but these appeared moti-
vated by specific interests of certain groups, such as ones more interested in fertility (i.e., youn-
ger respondents and females). Willingness to pay for IVF was highest in the age groups that
are likely to be most concerned about parenthood, with respondents younger than age 35 will-
ing to pay the highest amount, and 32% of respondents age 45 or older unwilling to pay any
amount for IVF. A previous survey found men less supportive of IVF than women and
reported that when respondents knew someone with infertility problems, they were more
likely to support reimbursement [22]. Interestingly in our survey more men (23.9%) than
women (17.2%) reported that they or their partner had considered or had IVF.
The majority of respondents of our survey agreed that IVF should be publicly funded to
some extent, with the strongest support (66%) for public funding for infertility due to a disease
or its treatment (i.e., cancer treatment) or for primary infertility. In general, support for public
funding was consistent with results reported previously in a survey of European respondents
in which the cost of IVF was presented as being similar to that of a hip replacement [22]. Thus,
government reimbursement for IVF may garner additional support if the public is educated to
understand that infertility is a medical, rather than social issue. Fifty-nine percent of respon-
dents believed public funding should be limited to one child. This may be linked to the fact
that, in most of the countries surveyed, the financial burden of infertility treatments is partly
alleviated by the social security system. This is particularly true in France where infertility
treatments are fully reimbursed and where willingness to pay (WTP) is the lowest of all
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countries. WTP in our survey may have been biased due to the low starting point (0 €) that
was presented to the respondents. A recent paper that explored the reliability and validity of
surveys for estimating willingness to pay [23] found that a strong anchoring/starting point bias
was evident in surveys that presented a low starting value, with lower WTP values obtained.
Overall, we observed strong support by respondents of most countries to permit IVF access
for single women and same-sex female couples. More respondents in our survey supported
egg and sperm donation (78%) than were willing to consider IVF for themselves (46%), sug-
gesting societal support for the procedure, even among respondents that would not undergo it.
There were differences in responses depending on the country of residence and this factor
may reflect variation in cultural, social, and religious norms [23]. For example, 38% of respon-
dents from Italy (with a large Catholic influence) would not consider IVF and were the least
supportive of IVF and of gamete donation.
In Sweden, the law changed in April 2016 to permit IVF access for single and same sex
women; access is also permitted in Germany, Spain, and the UK, but not in France and Italy
[24]. The results of a study examining the impact of regulations and public financing in Europe
on the utilization of IVF showed that countries providing the most generous public financing
tend to restrict access [25]. Furthermore, an international survey on the impact of affordability
on access to fertility treatment conducted in 2014 analyzed data from 30 high and upper-mid-
dle income countries (which included the countries in the present study) and showed that
lower costs for infertility treatments were positively correlated with an increase in utilization
[26]. Thus, the findings from this current survey, which shows support for reimbursement of
IVF, may be useful in convincing legislators that a change in public policy to provide more
financial support for IVF may be acceptable to their constituents and that lessening of restric-
tions to access could increase utilization. This could help alleviate population decline and its
associated implications [24].
One issue of concern is over-optimism about IVF success as views could affect childbearing
efforts and delay pregnancy to later in life when fecundity is suboptimal. Although the item
investigating opinion on success rates in our survey did not specify whether it was related to a
single fresh IVF cycle, additional pregnancy chances using cryopreserved embryos, or the use
of multiple IVF cycle, respondents’ expectations of IVF success appear to be high as reflected
by an estimated success rate of IVF of 47%. Actual pregnancy rates following IVF are reported
to be 25% to 35%, per single IVF cycle and fresh embryo transfer [27], suggesting that our
respondents, on average, had falsely high expectations about the success rate concerning IVF
treatment.
Postponing childbirth has become common in Western countries especially among
college-educated women [28]. Over-optimism of IVF success rates may lead to over-reliance
on IVF as way of compensating for infertility, especially when due to delayed childbearing
[29–31]. More than half of the respondents in this survey believed that the availability of
IVF treatment encourages a delay in conception. Education of young men and women
about age-related decrease in fertility as well as IVF procedures and success rates over single
versus multiple cycles may help inform family planning and reduce reliance on fertility
interventions.
Limitations of our survey include the possibility that the population responding may not be
representative of the actual population. Indeed, respondents were invited from volunteer par-
ticipants of an online panel [18]. In general, information on employment, socioeconomic, and
professional status of the respondents is lacking. Data on fertility status were not collected,
except to determine that 20% of the respondents had either considered or undergone IVF
treatment and are likely to have had (or at least know someone with) fertility issues. Respon-
dents with IVF experience may be less supportive if their experience was with failed IVF [23].
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Given that we disproportionately sampled from people in childbearing age, there potentially is
an over-representation of people interested in fertility. A recent survey examined the attitudes
of 146 fertile vs 93 infertile women in Lithuania and found that fertile respondents were more
likely to believe that IVF should be limited to married couples within a defined age limit and
should include a psychological assessment [32]. Infertile couples were more likely to view pub-
lic funding as a key component of IVF treatment. Thus, it is unknown to what extent key fac-
tors such as fertility status would have affected the responses in the current survey. The
attitudes of people older than age 55 are of questionable value for several of the survey items;
however, the majority of the survey respondents were of child-bearing age. Although willing-
ness to pay for IVF may not be as relevant for the youngest or oldest respondents, inclusion
of the entire population is helpful in gauging support for public funding. Our analysis was
designed as univariate with the intention to keep it simple. The purpose of the survey is to pro-
vide the general European view from the largest countries in Western Europe, and it was not
planned to explore or highlight differences between countries. Thus, each country’s data were
not weighted by country population size; however, Sweden is the only country with a markedly
different population size. Due to the number of countries, demographic variables, and rela-
tively large number of questions, our objective is to provide a straightforward reporting of the
results of this large survey. The lack of information on social beliefs and socioeconomic char-
acteristics did not allow us to determine the impact of social variables on our findings and also
limited our ability to conduct further analyses that may have explored reasons for restriction
of IVF access for younger age groups or to one pregnancy. Finally, the average time it took
respondents to complete the survey (7.5 min) was short and this factor likely contributed to
the high response rate (6,110/8,682, 70% response).
The LIFE survey is one of the largest to date and provides information about the public’s
perception on IVF treatment, its acceptance, funding, and limits to availability. Our multina-
tional sample covered countries where policies regarding treatment reimbursement are differ-
ent. The survey results demonstrate an overall positive attitude of the general population
toward IVF and toward public funding of infertility and fertility treatment among European
respondents. These findings may potentially be utilized to guide and inform discussions
among patients and prescribers and among legislators and payers for the funding of these
procedures.
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